CN115443333A - 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 - Google Patents
一种基因编辑的造血干细胞及其与car-t细胞的联合应用 Download PDFInfo
- Publication number
- CN115443333A CN115443333A CN202280003215.1A CN202280003215A CN115443333A CN 115443333 A CN115443333 A CN 115443333A CN 202280003215 A CN202280003215 A CN 202280003215A CN 115443333 A CN115443333 A CN 115443333A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- surface protein
- cell surface
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 title claims description 366
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims description 63
- 238000000034 method Methods 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 163
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 163
- 230000035772 mutation Effects 0.000 claims description 122
- 102000018697 Membrane Proteins Human genes 0.000 claims description 104
- 108010052285 Membrane Proteins Proteins 0.000 claims description 104
- 239000002773 nucleotide Substances 0.000 claims description 59
- 125000003729 nucleotide group Chemical group 0.000 claims description 59
- 108020004414 DNA Proteins 0.000 claims description 52
- 238000012217 deletion Methods 0.000 claims description 48
- 230000037430 deletion Effects 0.000 claims description 48
- 102000053602 DNA Human genes 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 39
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 36
- 238000010362 genome editing Methods 0.000 claims description 36
- 230000002147 killing effect Effects 0.000 claims description 36
- 210000004881 tumor cell Anatomy 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 20
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 17
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 17
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 16
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 16
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 16
- 230000004075 alteration Effects 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 16
- 101150044797 CD33 gene Proteins 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 238000010354 CRISPR gene editing Methods 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000037436 splice-site mutation Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 230000002489 hematologic effect Effects 0.000 claims description 7
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 4
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 229940125644 antibody drug Drugs 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 230000008439 repair process Effects 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 16
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 16
- 238000010008 shearing Methods 0.000 description 16
- 238000011529 RT qPCR Methods 0.000 description 14
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 101150038500 cas9 gene Proteins 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 13
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 230000007017 scission Effects 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108091033409 CRISPR Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 9
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 208000024908 graft versus host disease Diseases 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000037433 frameshift Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000566576 Tyto Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- -1 RNP compound Chemical class 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101100091360 Homo sapiens RNPC3 gene Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100026085 RNA-binding region-containing protein 3 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
提供了改变细胞抗原表位的方法以及利用该方法制备的细胞。还提供了所述细胞与CAR‑T细胞或抗体类药物联合应用治疗肿瘤的方法和药物组合物。具有抗原表位改变的细胞不被CAR‑T或抗体类药物杀伤，可输入患者体内，以缓解CAR‑T产品或抗体类药物在肿瘤治疗中的副作用。
Description
PCT国内申请，说明书已公开。
Claims (45)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110461504 | 2021-04-27 | ||
| CN2021104615043 | 2021-04-27 | ||
| PCT/CN2022/089600 WO2022228471A1 (zh) | 2021-04-27 | 2022-04-27 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115443333A true CN115443333A (zh) | 2022-12-06 |
Family
ID=83846706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280003215.1A Pending CN115443333A (zh) | 2021-04-27 | 2022-04-27 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115443333A (zh) |
| WO (1) | WO2022228471A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116516007B (zh) * | 2023-04-18 | 2024-01-19 | 华中科技大学同济医学院附属协和医院 | Cd19表达的检测方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290939A (zh) * | 2015-10-16 | 2018-07-17 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| CN110662554A (zh) * | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | 用于抑制谱系特异性蛋白质的组合物和方法 |
| CN112189022A (zh) * | 2018-05-24 | 2021-01-05 | 詹森生物科技公司 | 抗cd33抗体、抗cd33/抗cd3双特异性抗体及其用途 |
| WO2021062227A2 (en) * | 2019-09-27 | 2021-04-01 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108463227A (zh) * | 2015-11-04 | 2018-08-28 | 宾夕法尼亚大学董事会 | 在造血干细胞中基因编辑的方法和组合物 |
| CN113474452A (zh) * | 2019-01-16 | 2021-10-01 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
-
2022
- 2022-04-27 WO PCT/CN2022/089600 patent/WO2022228471A1/zh active Application Filing
- 2022-04-27 CN CN202280003215.1A patent/CN115443333A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290939A (zh) * | 2015-10-16 | 2018-07-17 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| CN110662554A (zh) * | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | 用于抑制谱系特异性蛋白质的组合物和方法 |
| CN112189022A (zh) * | 2018-05-24 | 2021-01-05 | 詹森生物科技公司 | 抗cd33抗体、抗cd33/抗cd3双特异性抗体及其用途 |
| WO2021062227A2 (en) * | 2019-09-27 | 2021-04-01 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
Non-Patent Citations (3)
| Title |
|---|
| HUMBERT等: "Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2", BLOOD, vol. 132, 29 November 2018 (2018-11-29) * |
| KIM等: "Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia", CELL, vol. 173, 31 May 2018 (2018-05-31), pages 1439 - 1453 * |
| LAMBA等: "CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531", J CLIN ONCOL, vol. 35, no. 23, 23 June 2017 (2017-06-23), pages 3, XP055579669, DOI: 10.1200/JCO.2016.71.2513 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022228471A1 (zh) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108174604B (zh) | 用于实体瘤靶向的双特异性car t细胞 | |
| JP2020195393A (ja) | 養子細胞療法用の操作された細胞 | |
| KR20210008502A (ko) | 암을 치료하기 위한 방법 및 조성물 | |
| CN111479917A (zh) | 经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞 | |
| CN116064401A (zh) | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 | |
| EP4176048A1 (en) | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence | |
| JP2022512882A (ja) | 抗ｃｄ３３免疫細胞癌療法 | |
| CN111263808B (zh) | 一种靶向HPK1的gRNA和一种编辑HPK1基因的方法 | |
| US20200231699A1 (en) | Anti-liv1 immune cell cancer therapy | |
| WO2018068257A1 (zh) | 通用型car-t细胞及其制备方法和用途 | |
| CN114317607A (zh) | 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法 | |
| EP4058053A1 (en) | Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70 | |
| CN115443333A (zh) | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 | |
| US20230303713A1 (en) | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof | |
| KR20220125805A (ko) | Cd70-양성 종양을 표적화하기 위해 천연 킬러 세포를 가공하는 방법 | |
| EP4073267A1 (en) | Method for obtaining nucleic acid for sequencing | |
| WO2023159136A2 (en) | Epitope engineering of cell-surface receptors | |
| WO2022267842A1 (en) | Disruptions of pdcd1, adora2a, and ctla4 genes and uses thereof | |
| CN113549157B (zh) | 双靶向嵌合抗原受体及其应用 | |
| CN116715750B (zh) | 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞 | |
| WO2023205705A2 (en) | Allogeneic t cells for treatment of hematological malignancies | |
| Salim | The Characterization and Therapeutic Targeting of CD133 in Human Glioblastoma | |
| Lill et al. | Uses of CRISPR/Cas9 gene editing in chimeric antigen receptor T cell therapy to treat B-cell acute lymphoblastic leukemia | |
| WO2023111913A1 (en) | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption | |
| WO2023233342A2 (en) | Gene-edited natural killer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231207 Address after: 201203 5th Floor, Building 77-78, Lane 887, Zuchongzhi Road, Zhangjiang, Pudong New Area, Shanghai Applicant after: Shanghai Reindeer Biotechnology Co.,Ltd. Applicant after: Nanjing reindeer biomedical Co.,Ltd. Address before: 201203 5th Floor, Building 77-78, Lane 887, Zuchongzhi Road, Zhangjiang, Pudong New Area, Shanghai Applicant before: Shanghai Reindeer Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right |